Physician profile
Sirtaz S Sibia
NPI 1679518195
$33,620.58
in general payments reported to CMS, 2019-2025
42 companies · $6,799 in 2025
The $6,799 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,693 · 2020: $3,339 · 2021: $3,249 · 2022: $5,626 · 2023: $4,970 · 2024: $6,945 · 2025: $6,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Travel and Lodging: $3,436 · Honoraria: $1,616 · Consulting Fee: $1,200 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,274.13 |
| Travel and Lodging | $3,435.64 |
| Honoraria | $1,616.25 |
| Consulting Fee | $1,200.00 |
| Education | $187.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $6,954.60 | 2019-2025 | Lensx, Clareon, Unity |
| New World Medical,INC. | $4,043.82 | 2022-2025 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $3,750.00 | 2020-2021 | |
| Katena Products, INC. (Dba Corza Medical) | $2,500.00 | 2022 | |
| Abbvie INC. | $2,486.94 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Alphagan P |
| Johnson & Johnson Surgical Vision, INC. | $1,712.22 | 2019-2025 | Veritas Vision System, Tecnis Iol, Amo Phaco Needle |
| Argenx US, INC. | $1,672.08 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Mallinckrodt Hospital Products INC. | $1,344.66 | 2022-2025 | Acthar |
| Glaukos Corporation | $1,150.41 | 2019-2025 | Idosetr, Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $1,059.97 | 2022-2025 | Envista Mx60 Iol, Stellaris, Envista Envy Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $976.56 | 2019-2021 | |
| Allergan, INC. | $808.44 | 2019-2022 | |
| Sight Sciences, INC. | $745.68 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Horizon Therapeutics Plc | $662.43 | 2021-2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $571.67 | 2022-2023 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $491.41 | 2022-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $415.06 | 2024-2025 | Purified Cortrophin Gel |
| Rxsight INC | $345.00 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Amgen INC. | $274.00 | 2024-2025 | Tepezza |
| Dompe US, INC. | $268.11 | 2021-2025 | Oxervate |
| Quidel Corporation | $232.66 | 2021-2022 | |
| Ocular Therapeutix, INC. | $198.33 | 2021-2023 | Dextenza |
| Novartis Pharmaceuticals Corporation | $142.16 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $132.90 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $122.56 | 2023 | Eylea Hd |
| Shire North American Group INC | $78.65 | 2019 | |
| Kala Pharmaceuticals, INC. | $67.84 | 2019-2021 | |
| Oyster Point Pharma, INC. | $64.14 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $40.39 | 2024-2025 | Xdemvy |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Harrow Eye, LLC | $36.32 | 2024-2025 | Vevye |
| Genentech USA, INC. | $30.20 | 2022 | |
| Biotissue Holdings INC. | $28.31 | 2020-2021 | |
| Alcon Research LLC | $27.50 | 2019 | |
| Tearlab Corp | $27.15 | 2022 | |
| Lensar, INC. | $26.51 | 2024 | Lensar Laser System |
| Regeneron Healthcare Solutions, INC. | $22.68 | 2021 | |
| Merz Pharmaceuticals, LLC | $21.40 | 2025 | Xeomin |
| Merz North America, INC. | $20.42 | 2020 | |
| Astellas Pharma US INC | $16.61 | 2024 | Izervay |
| Lombart Brothers, INC. | $11.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sirtaz Sibia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.